Amanda Townsend
YOU?
Author Swipe
View article: Bacterial Infections and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple-Negative Breast Cancer Cells
Bacterial Infections and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple-Negative Breast Cancer Cells Open
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor clinical outcomes. Emerging evidence suggests that the tumor-associated microbiome may influence disease progression and ther…
View article: First-line panitumumab, irinotecan, and trifluridine/tipiracil in patients with RAS wildtype metastatic colorectal cancer: PIT protocol
First-line panitumumab, irinotecan, and trifluridine/tipiracil in patients with RAS wildtype metastatic colorectal cancer: PIT protocol Open
Background: Trifluridine/tipiracil (TT) is an oral fluoropyrimidine (FP) currently utilised in later-line therapy for metastatic colorectal cancer, with a unique mechanism of action and clinical activity in patients with prior FP failure. …
View article: Bacterial Infection and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple‐Negative Breast Cancer Cells
Bacterial Infection and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple‐Negative Breast Cancer Cells Open
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor clinical outcomes. Emerging evidence suggests that the tumor-associated microbiome may influence disease progression and ther…
View article: Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer
Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer Open
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options and inconsistent response to immune checkpoint inhibitors (ICIs). Emerging evidence indicates that tumor-associated bacteria may sha…
View article: Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer
Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer Open
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited treatment options. While immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have shown clinical benefit, response rates remain variable, and mec…
View article: A Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis, and Breast Cancer
A Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis, and Breast Cancer Open
The breast tissue microbiome has been increasingly recognized as a potential contributor to breast cancer development and progression. However, inconsistencies in microbial composition across studies have hindered the identification of def…
View article: Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis and Breast Cancer
Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis and Breast Cancer Open
The breast tissue microbiome has been increasingly recognized as a potential contributor to breast cancer development and progression. However, inconsistencies in microbial composition across studies have hindered the identification of def…
View article: Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells
Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells Open
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and high resistance to chemotherapy. Doxorubicin is commonly used, but its efficacy is limited by variable sensitivity and resistance.…
View article: Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells
Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells Open
Background: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options and high drug resistance. Doxorubicin is commonly used for TNBC, but variable sensitivity across subtypes, resista…
View article: Diagnostic and prognostic significance of circulating secreted frizzled‐related protein 5 in colorectal cancer
Diagnostic and prognostic significance of circulating secreted frizzled‐related protein 5 in colorectal cancer Open
Background Secreted Frizzled‐Related Protein 5 (SFRP5) modulates Wnt signalling pathways, affecting diverse biological processes. We assessed the diagnostic and prognostic value of circulating SFRP5 (cSFRP5) in colorectal cancer (CRC) Meth…
View article: Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease
Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease Open
Secreted Frizzled-Related Protein 5 (SFRP5) modulates Wnt signalling pathways, affecting diverse biological processes. We assessed the diagnostic and prognostic value of circulating SFRP5 (cSFRP5) in colorectal cancer (CRC). Plasma cSFRP5 …
View article: Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer Open
The standard cetuximab dosing regimen may not be optimal for all patients. Further pharmacokinetic studies are needed to optimize cetuximab dosing given the potential improvement in OS.
View article: Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis
Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis Open
Background Colorectal cancer with synchronous liver‐only metastasis is managed with a multimodal approach, however, optimal sequencing of modalities remains unclear. Methods A retrospective review of all consecutive rectal or colon cancer …
View article: Data from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Data from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety and efficacy of the combination of irinotecan, panitumumab, and …
View article: Figure S1 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Figure S1 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Consort Diagram
View article: Figure S1 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Figure S1 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Consort Diagram
View article: Figure S2 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Figure S2 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Kaplan-Meier Survival Curves for Biomarker Substudy (n=33)
View article: Figure S2 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Figure S2 from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Kaplan-Meier Survival Curves for Biomarker Substudy (n=33)
View article: Data from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Data from Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer Open
Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety and efficacy of the combination of irinotecan, panitumumab, and …
View article: The Effect Of Age And Menstrual Cycling On Gene Expression Profiling Tests
The Effect Of Age And Menstrual Cycling On Gene Expression Profiling Tests Open
Problem Statement: Gene expression profiling tests are becoming a critical part of the clinician's toolbox to guide treatment decisions for early-stage estrogen receptor positive (ER+) breast cancer patients. Women over the age of 50 with …
View article: Survey of germline variants in cancer‐associated genes in young adults with colorectal cancer
Survey of germline variants in cancer‐associated genes in young adults with colorectal cancer Open
Colorectal cancer (CRC) incidence in young adults is rising. Identifying genetic risk factors is fundamental for the clinical management of patients and their families. This study aimed to identify clinically significant germline variants …
View article: Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models
Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models Open
Key problems of chemotherapies, as the mainstay of treatment for triple-negative breast cancer (TNBC), are toxicity and development of tumour resistance. Using response surface methodology, we previously optimised the combination of epimer…
View article: Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours
Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours Open
Background The Oncotype DX 21-gene Recurrence Score is predictive of adjuvant chemotherapy benefit for women with early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. In premenopausal women, fluctuations in estrogen a…
View article: Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments
Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments Open
Tumour angiogenesis plays a key role in tumour growth and progression. The application of current anti-angiogenic drugs is accompanied by adverse effects and drug resistance. Therefore, finding safer effective treatments is needed. Ginseno…
View article: In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity
In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity Open
We previously showed how triterpene saponin bacopaside (bac) II, purified from the medicinal herb Bacopa monnieri, induced cell death in colorectal cancer cell lines and reduced endothelial cell migration and tube formation, and further de…
View article: Female breast cancer treatment and survival in South Australia: Results from linked health data
Female breast cancer treatment and survival in South Australia: Results from linked health data Open
Five-year disease-specific survival increased to 91% for 2010-2014. Most women had breast surgery (90%), systemic therapy (72%) and radiotherapy (60%). Less treatment applied for ages 80+ vs <50 years (aOR 0.10, 95% CI 0.05-0.20) and TNM s…
View article: Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response Open
Myxopapillary ependymoma (MPE) is a rare glial tumour mainly located in the areas of the conus medullaris, cauda equina and filum terminale of the spinal cord. Ectopic MPE tends to behave more aggressively and distant metastases are often …
View article: Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma Open
Survival outcome of patients with advanced gastric and OGJ adenocarcinoma whose disease progressed on first-line fluoropyrimidine and platinum-containing chemotherapy can be improved by chemotherapy and biological therapy. Biological thera…